Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/52080
Título: | Splenic marginal zone lymphoma - A clinicopathological study in a series of 16 patients | Autores/as: | Raya Sánchez, José María Ruano, J. A. Bosch, J. M. Golvano, E. Molero, T. Lemes, A. Cuesta, J. Brito, M. L. Hernández-Nieto, L. |
Clasificación UNESCO: | 32 Ciencias médicas 320504 Hematología |
Palabras clave: | SPLENIC MARGINAL ZONE LYMPHOMA CD5 BONE MARROW BIOPSY |
Fecha de publicación: | 2008 | Publicación seriada: | Hematology | Resumen: | Splenic marginal zone lymphoma (SMZL), characterized in the WHO classification of lymphoid tumors, is a rare disorder comprising less than 1% of lymphoid neoplasms; only a few series concerning this entity have been published. Although this type of lymphoma is well defined histologically, its histogenesis remains obscure. Moreover, specific biological markers are still lacking and immunophenotype profile is not specific. These and other reasons, such as the existence of cytogenetic subtypes, have led to some authors to suspect that SMZL constitutes a heterogeneous entity. We have analyzed a series of sixteen SMZL cases from four hospitals in our community, from a clinical, biological and pathological point of view. When compared with those reported in the literature, our findings show three main differences: our patients less frequently showed an intrasinusoidal bone marrow infiltration pattern; the presence of a serum monoclonal component was rarely seen; and CD5-positive SMZL cases appear to be more common than previously thought. | URI: | http://hdl.handle.net/10553/52080 | ISSN: | 1024-5332 | DOI: | 10.1179/102453308X316068 | Fuente: | Hematology[ISSN 1024-5332],v. 13(5), p. 276-281 |
Colección: | Artículos |
Citas SCOPUSTM
3
actualizado el 17-nov-2024
Citas de WEB OF SCIENCETM
Citations
6
actualizado el 17-nov-2024
Visitas
34
actualizado el 03-feb-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.